GleamWall
中文EN

CABA Cabaletta Bio, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1759138 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-19.5%
TTM EPS YoY44.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-89.5%
ROA-72.0%
ROIC (approx.)-479.6%
Asset turnover—

Leverage & solvency

Liabilities / assets15.6%
Debt / equity0.00x
Current ratio6.55x
Interest coverage-87.26x

Cash quality & payout

Operating cash flow / net income0.86x
Accruals ratio-10.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$47.14M$44.43M$37.35M$36.19M$39.82M$37.64M$29.02M$25.53M
SG&A expense$7.56M$7.59M$6.94M$6.42M$6.76M$8.27M$8.12M$8.25M
Operating income-$54.71M-$52.02M-$44.30M-$42.61M-$46.59M-$45.91M-$37.14M-$33.78M
Interest expense$511,000$517,000$636,000$555,000$584,000$571,000$294,000$748,000
Income tax$0$0$0$0$0$0$0$0
Net income-$53.05M-$51.02M-$43.52M-$41.92M-$44.87M-$45.13M-$35.94M-$32.59M
EBITDA-$54.36M-$51.65M-$43.96M-$42.26M-$46.24M-$45.44M-$36.65M-$33.32M
EPS (basic)-0.28-0.34-0.39—-0.44-0.73-0.71—
EPS (diluted)-0.28-0.34-0.39—-0.44-0.73-0.71—
Weighted avg. shares (diluted)186.78M151.16M112.03M—102.26M61.88M50.74M—
Balance sheet
Cash & equivalents$299.38M$225.10M$116.64M$82.98M$60.21M$145.61M$131.83M$163.96M
Short-term investments$0$0$0$50.62M$99.72M$49.07M—$0
Current assets$309.85M$231.03M$122.32M$138.87M$164.56M$198.41M$134.60M$166.68M
PP&E, net$1.01M$1.48M$1.58M$1.92M$2.06M$2.37M$2.64M$2.74M
Total assets$336.49M$256.73M$148.15M$165.08M$189.76M$224.50M$165.14M$185.05M
Current liabilities$47.33M$39.91M$41.51M$50.15M$45.73M$41.54M$33.99M$27.09M
Total liabilities$52.57M$46.13M$44.84M$53.03M$50.29M$46.02M$43.59M$32.71M
Shareholders' equity$283.92M$210.59M$103.31M$112.05M$139.47M$178.48M$121.55M$152.34M
Shares outstanding———100.48M96.27M91.45M—50.74M
Cash flow statement
Operating cash flow-$42.74M-$41.51M-$42.56M-$35.34M-$34.51M-$30.43M-$30.80M-$23.12M
Capital expenditure$142,000$0$0$205,000$78,000$161,000$785,000$376,000
Free cash flow-$42.89M-$41.51M-$42.56M-$35.55M-$34.59M-$30.59M-$31.59M-$23.50M
Investing cash flow-$142,000$0$50.96M$49.80M-$50.08M-$49.20M-$785,000$12.12M
Financing cash flow$117.19M$149.99M$25.27M$8.33M-$806,000$93.37M-$552,000$4.37M
Depreciation & amortization$347,000$371,000$337,000$348,000$345,000$468,000$485,000$468,000
Stock-based compensation$5.26M$5.50M$5.26M$4.26M$5.82M$5.71M$5.16M$5.41M

Free plan shows the latest 8 periods; Pro shows all 33 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.